BridgeBio’s Beyonttra gains approval in Japan for ATTR-CM treatment
Acoramidis is a selective small molecule that is orally administered. ATTR-CM is a progressive, restrictive cardiomyopathy that leads to heart failure. BridgeBio Cardiorenal chief medical officer Dr Jonathan